236 related articles for article (PubMed ID: 20853319)
21. Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease.
Masutani M; Nakagama H; Sugimura T
Cell Mol Life Sci; 2005 Apr; 62(7-8):769-83. PubMed ID: 15868402
[TBL] [Abstract][Full Text] [Related]
22. Chromatin architecture and functions: the role(s) of poly(ADP-RIBOSE) polymerase and poly(ADPribosyl)ation of nuclear proteins.
Faraone-Mennella MR
Biochem Cell Biol; 2005 Jun; 83(3):396-404. PubMed ID: 15959565
[TBL] [Abstract][Full Text] [Related]
23. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
Yap TA; Sandhu SK; Carden CP; de Bono JS
CA Cancer J Clin; 2011; 61(1):31-49. PubMed ID: 21205831
[TBL] [Abstract][Full Text] [Related]
24. Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions.
Beneke S; Diefenbach J; Bürkle A
Int J Cancer; 2004 Oct; 111(6):813-8. PubMed ID: 15300792
[TBL] [Abstract][Full Text] [Related]
25. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
[No Abstract] [Full Text] [Related]
26. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
de la Lastra CA; Villegas I; Sánchez-Fidalgo S
Curr Pharm Des; 2007; 13(9):933-62. PubMed ID: 17430191
[TBL] [Abstract][Full Text] [Related]
27. The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.
Sandhu SK; Yap TA; de Bono JS
Curr Drug Targets; 2011 Dec; 12(14):2034-44. PubMed ID: 21777194
[TBL] [Abstract][Full Text] [Related]
28. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art.
De Vos M; Schreiber V; Dantzer F
Biochem Pharmacol; 2012 Jul; 84(2):137-46. PubMed ID: 22469522
[TBL] [Abstract][Full Text] [Related]
29. Poly (ADP-ribose) polymerase inhibitors in cancer treatment.
Mason KA; Raju U; Buchholz TA; Wang L; Milas ZL; Milas L
Am J Clin Oncol; 2014 Feb; 37(1):90-100. PubMed ID: 22495455
[TBL] [Abstract][Full Text] [Related]
30. Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy.
Haince JF; Rouleau M; Hendzel MJ; Masson JY; Poirier GG
Trends Mol Med; 2005 Oct; 11(10):456-63. PubMed ID: 16154385
[TBL] [Abstract][Full Text] [Related]
31. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.
Cepeda V; Fuertes MA; Castilla J; Alonso C; Quevedo C; Soto M; Pérez JM
Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):39-53. PubMed ID: 18221025
[TBL] [Abstract][Full Text] [Related]
32. Poly(ADP-ribosyl)ation, PARP, and aging.
Beneke S; Bürkle A
Sci Aging Knowledge Environ; 2004 Dec; 2004(49):re9. PubMed ID: 15590998
[TBL] [Abstract][Full Text] [Related]
33. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
Ratnam K; Low JA
Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
[TBL] [Abstract][Full Text] [Related]
34. Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.
Jones P; Wilcoxen K; Rowley M; Toniatti C
J Med Chem; 2015 Apr; 58(8):3302-14. PubMed ID: 25761096
[TBL] [Abstract][Full Text] [Related]
35. Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity.
Kuo ML; Shen SC; Yang CH; Chuang SE; Cheng AL; Huang TS
Oncogene; 1998 Oct; 17(17):2225-34. PubMed ID: 9811453
[TBL] [Abstract][Full Text] [Related]
36. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications.
Drew Y; Plummer R
Drug Resist Updat; 2009 Dec; 12(6):153-6. PubMed ID: 19939726
[TBL] [Abstract][Full Text] [Related]
37. Poly(ADP-ribose): PARadigms and PARadoxes.
Bürkle A; Virág L
Mol Aspects Med; 2013 Dec; 34(6):1046-65. PubMed ID: 23290998
[TBL] [Abstract][Full Text] [Related]
38. Ageing and PARP.
Bürkle A; Diefenbach J; Brabeck C; Beneke S
Pharmacol Res; 2005 Jul; 52(1):93-9. PubMed ID: 15911337
[TBL] [Abstract][Full Text] [Related]
39. DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy.
Pillay N; Brady RM; Dey M; Morgan RD; Taylor SS
Prog Biophys Mol Biol; 2021 Aug; 163():160-170. PubMed ID: 33524442
[TBL] [Abstract][Full Text] [Related]
40. Trapping Poly(ADP-Ribose) Polymerase.
Shen Y; Aoyagi-Scharber M; Wang B
J Pharmacol Exp Ther; 2015 Jun; 353(3):446-57. PubMed ID: 25758918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
